ArticleMolecular biology reports2025
Investigation of the association of tRNA-derived fragments (tRF-17-79MP9PP and tRF-18-79MP9P04) with prostate cancer.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThis study investigates the association between the levels of two tRNA-derived fragments, tRF-17-79MP9PP and tRF-18-79MP9P04, and the pathophysiology of prostate cancer (PCa). MATERIALS AND
methodsForty patients were included: 8 with benign prostatic hyperplasia (BPH) and 32 with different PCa grades. Total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissues, and the levels of tRF-17-79MP9PP and tRF-18-79MP9P04 were analyzed.
resultsThe abundance of tRF-17-79MP9PP increased progressively with cancer grade (p < 0.001), with the highest levels observed in advanced PCa. Interestingly, BPH also showed higher tRF-17-79MP9PP level than low- and mild-grade PCa. Level of tRF-18-79MP9P04 was comparable between BPH and low-grade PCa, but significantly higher in mild, high, and advanced grades (p < 0.001). Furthermore, PSA levels were significantly correlated with both tRF-17-79MP9PP and tRF-18-79MP9P04 in PCa patients (p < 0.001), but not in the BPH group. DISCUSSION: Both tRF-17-79MP9PP and tRF-18-79MP9P04 appear to play important roles in prostate cancer, demonstrating potential oncogenic behavior in advanced stages, which contrasts with previous studies reporting tumor-suppressive effects.
conclusionThese findings indicate that elevated levels of these tRNA-derived fragments may serve as potential biomarkers for distinguishing between different grades of PCa.
Indexed as
Identifiers
41129034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.